11

2019-03


Minhai Biotechnology’s 2019 International Women’s Day “Beauty Lights Up Life” DIY Handmade Floral Arrangement Event

To celebrate International Women’s Day on March 8, the Minhai Bio Trade Union organized a “Beauty Lights Up Life” DIY floral‑arranging workshop in the multi‑purpose hall on the second floor of the company canteen. The event aimed to cultivate among the company’s female employees a refined appreciation for beauty—encouraging them to recognize, cherish, pursue, and create beauty—thereby enhancing their quality of life and ensuring a healthy, uplifting, joyful, warm, memorable, and meaningful celebration.

03

2019-02


Visiting to Bring Warmth, Offering Comfort to the Heart: Minhai Bio Launches Spring Festival Outreach and Care Activities

On February 2, 2019, amid the cold winter of the twelfth lunar month and with the festive spirit steadily growing, the Party branch and the trade union of Minhai Biotechnology jointly organized a Spring Festival visit to offer condolences and support to employees facing financial hardship, bringing warmth in the depths of winter and New Year blessings to struggling staff members and retired employees.

04

2019-01


Warm congratulations to Minhai Company on successfully obtaining certification for its Intellectual Property Management System (Standardization Certification).

The company initiated its intellectual property management system standardization efforts in May 2018. Following seven months of intensive preparation, on December 11–12, 2018, it hosted a three-member audit team from Zhongzhi (Beijing) Certification Co., Ltd., which assessed the establishment and operation of the company’s intellectual property management system. Liu Jiankai, the company’s Executive Deputy General Manager and representative of the IP management function, along with heads and relevant personnel from the Research & Development Department, Human Resources Department, Finance Department, General Office, Procurement and Warehousing Department, Marketing Department, R&D Center, and Production Operations Center, all participated in the audit.

29

2018-12


The Pakistan Drug Regulatory Authority has visited Minhai to conduct an inspection of the leprosy bivalent vaccine.

Recently, a five-member delegation comprising two inspectors from the Pakistan Medicines Regulatory Authority—Abdul Rashid Shaikh and Muhammad Amin—and three agents, including Shahzad Hussain Chaudhry, visited Minhai to conduct an inspection of the measles–rubella combined attenuated live vaccine (hereinafter referred to as the “MR vaccine”). Company executives attached great importance to this inspection by the Pakistan Medicines Regulatory Authority, instructing all levels of the organization to take it seriously, provide full cooperation, and make thorough preparations to ensure the smooth completion of the inspection.

29

2018-12


Pakistan has resumed production of the measles vaccine, with the vaccine concentrate supplied by Beijing Minhai, a wholly owned subsidiary of Kintor Pharmaceutical.

According to a December 27, 2018 report by Pakistan’s The Express Tribune, as measles makes a resurgence, the National Institute of Health in Pakistan has resumed production of measles vaccine after an interruption of nearly seven years. The vaccine’s bulk antigen is being supplied by Beijing Minhai Biotechnology Co., Ltd., a wholly owned subsidiary of Shenzhen Kangtai Biological Products Co., Ltd. of China. This marks the first time China has exported measles vaccine bulk antigen to Pakistan.

< 1...232425...31 >